ArticleAnnals of hematology2026
A survey on the management of chronic myeloid leukemia in chronic phase from the perspectives of both patients and physicians.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lifespan of patients with chronic phase chronic myeloid leukemia undergoing tyrosine kinase inhibitor treatment has nearly reached that of the general population. However, treatment switching due to resistance or intolerance demonstrates the significance of effective communication between patients and physicians in decision-making. This study aimed to evaluate priorities, expectations, and perceptions of managing CML-CP from the perspective of both patients and physicians in Türkiye. This cross-sectional survey study was conducted from July to December 2024 by the Turkish Society of Hematology. A total of 129 hematologists completed a web-based survey, while 120 patients receiving TKI treatment completed a structured telephone survey. Eleven common questions were analyzed descriptively to compare perspectives. Patients (53% male; median age 54 years) and physicians agreed on essential information to be communicated at treatment start, although priorities differed. Patients prioritized information about disease progression, daily life impact, and treatment effectiveness, whereas physicians focused on treatment safety, patient monitoring, and follow-up assessments. Patients (40.8%) emphasized treatment effectiveness when switching therapies, while physicians (46.7%) focused on the manageability of adverse events. Approximately 25% of patients reported suboptimal adherence, mostly due to forgetfulness (52%). Follow-up visits occurred every 2 to 3 months, with a mean duration of approximately 10 min. Although patients and physicians shared broadly similar views, discrepancies existed in their prioritization of factors and overall opinions. Patients expressed greater optimism regarding the disease impact on their daily lives. Enhancing communication between patients and physicians, as well as promoting shared decision-making during treatment transitions, may improve adherence and disease management outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.